PBAC tightens up on proton-pump inhibitors

Treatment of gastrointestinal acid related disorders with proton-pump inhibitors (PPIs) will change in response to concerns from the Drug Utilisation Sub Committee of the Pharmaceutical Benefits Advisory Committee (PBAC) At its July 2018 meeting and following consultation with GESA, the PBAC has recommended increasing the restrictions on all standard dose PPIs from Restricted Benefit to ...

Already a member?

Login to keep reading.

© 2021 the limbic